Uttar Pradesh: Man dies after platelet transfusion in Prayagraj

Uttar Pradesh: Man dies after platelet transfusion in Prayagraj
Photo for representative purpose only
PRAYAGRAJ: A probe has been ordered into the death of a 30-year-old man who, according to his family members, died after wrong platelets transfusion.
His family members said that he died after three units of platelets were transfused. His family claimed that it was a fake platelet made of mosambi juice (sweet lime).
Taking cognizance of the incident, deputy CM and health minister Brajesh Pathak said that strict action would be taken against those found guilty in the case.
Senior superintendent of police (Prayagraj) Shailesh Kumar Pandey told TOI that two teams have been constituted to probe the case. “We would first ascertain the actual cause of the death and then initiate legal action accordingly. We have also consulted the chief medical officer (Prayagraj) Dr. Nanak Saran regarding the incident.”
The family members of the man, who was suffering from dengue, alleged that his condition deteriorated after undergoing three units of platelet transfusion at a private hospital in Dhoomanganj on Wednesday. They also claimed that Rs 9,000 was spent on arranging the plasma and when it was transfused, the condition of the patient deteriorated and they shifted him to another hospital in the Georgetown area.
On arrival, the doctors there told them that the case was complicated and the patient died. The family members claimed that when the doctors at Georgetown hospital saw the one remaining unit of platelets, they said it was very thin and made of mosambi juice. It had been procured by the previous hospital and the file was bearing the logo of a government hospital.
The SSP said the probe report would reveal the exact cause of death and teams have been probing the network of agents involved in illegal sale or purchase of platelets. Meanwhile, doctors have advised people to take blood platelets from authorities blood banks only.
FOLLOW US ON SOCIAL MEDIA
FacebookTwitterInstagramKOO APPYOUTUBE
Start a Conversation
end of article